According to Zhitong Finance App News, Shengda Biotech (603079.SH) disclosed the 2026 semi-annual report. During the reporting period, the company achieved operating income of 389 million yuan, a year-on-year decrease of 2.91%; net profit attributable to shareholders of listed companies was 20.53 million yuan, a year-on-year decrease of 45.70%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 18.92 million yuan, a year-on-year decrease of 46.03%; and basic earnings per share were 0.11 yuan.

During the reporting period, the company's operating income, profit, and earnings per share declined year-on-year, mainly due to the uncertainty of the US tariff policy in 2025, which prompted downstream customers of the company's biological preservatives and functional ingredient products to prepare goods to cope with risks. As a result, customers entered the inventory digestion stage in the first half of 2026, and product sales and revenue declined sharply year on year. Due to the high gross margin of functional ingredient products, the decline in sales share had a certain impact on the overall profit level; at the same time, due to fluctuations in the US dollar exchange rate, the company's exchange losses increased year-on-year during the reporting period, which further led to a year-on-year decrease in profit.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.